ABSTRACT Methotrexate (MTX) conjugated to a Mr 3000 poly(L-Lys) markedly inhibits the growth of (5) . We have also shown that the membrane transports of MTX and MTX-poly(Lys) can be inhibited independently. Thiamine pyrophosphate, which inhibits the uptake of MTX, protects cells against free MTX but not against conjugated MTX. Heparin, which inhibits the uptake of MTX-poly(Lys), protects cells against the conjugate but not against the free drug. In the course of these experiments, we found that protection ofcells was optimal at low concentrations ofheparin but partially reversed at higher concentrations (6). We now present evidence that this unexpected reappearance of cytotoxicity is due to the formation ofa complex between the drug-conjugate and heparin (MTX-poly(Lys)-heparin). This complex is transported by a different process, is inhibitory to dihydrofolate reductase in vitro, and does not require intracellular degradation to exert strong cytotoxic effects.
addition of 0.5-to 2.5-fold heparin but remains at 15-20% of control in 2.5-to 50-fold heparin excess. Heparin addition at first markedly inhibits but, at high concentration, restores the growth inhibitory effect of MTX-poly(Lys). In excess heparin, MTX- poly(Lys) is transported as a heparin complex. Because reduced transport (15-20%) is sufficient to cause a 90% inhibition of cell growth, MTX-poly(Lys) apparently gains pharmacologic potency when complexed to heparin. This gain can be related to a greater inhibitory effect on dihydrofolate reductase and to a different mode of transport. The inhibitory effect of MTX-poly(Lys) on dihydrofolate reductase in vitro is increased nearly 100-fold in the presence ofexcess heparin but remains less than that offree MTX. Unlike that of MTX-poly(Lys), the transport of MTX-poly-(Lys)-heparin has the characteristics and efficiency of a receptormediated process. It proceeds by endocytosis but is not, as in the case of uncomplexed conjugate, followed by the intracellular generation of pharmacologically active breakdown products that would account for cytotoxicity. These observations raise the possibility that at least part of the MTX-poly(Lys)-heparin reaches cellular dihydrofolate reductase in the form of macromolecular complexes that escape from entrapment in endocytotic structures. Our data illustrate-a way to overcome drug resistance by taking advantage ofthe specific uptake ofa macromolecular drug carrier. They offer a method of drug delivery in which heparin improves selectivity and decreases the unwanted toxicity inherent to polycationic carriers.
Poly(Lys) can be used as a carrier in the membrane transport of proteins (1) and drugs (2) in mammalian cells. The antifolate agent methotrexate (MTX) is taken up by cells at a higher rate in the form ofpoly(Lys) conjugates than in the form offree drug, and this increased uptake can overcome drug resistance due to deficient MTX transport (2) . Although the poly(D-Lys) conjugate of MTX [MTX-poly(D-Lys)] enters cells as efficiently as its isomeric counterpart, it is completely inactive as an inhibitor of cell growth (3) . Both isomeric conjugates fail to inhibit dihydrofolate reductase (5, 6, 7, 8- (5) . We have also shown that the membrane transports of MTX and MTX-poly(Lys) can be inhibited independently. Thiamine pyrophosphate, which inhibits the uptake of MTX, protects cells against free MTX but not against conjugated MTX. Heparin, which inhibits the uptake of MTX-poly(Lys), protects cells against the conjugate but not against the free drug. In the course of these experiments, we found that protection ofcells was optimal at low concentrations ofheparin but partially reversed at higher concentrations (6) . We now present evidence that this unexpected reappearance of cytotoxicity is due to the formation ofa complex between the drug-conjugate and heparin (MTX-poly(Lys)-heparin). This complex is transported by a different process, is inhibitory to dihydrofolate reductase in vitro, and does not require intracellular degradation to exert strong cytotoxic effects. Effect of Heparin on the Cytotoxicity of MTX and MTXPoly(Lys). Approximately 5 X 10' cells .of either CHO Pro-3 MtxRII5-3 or CHO WTT were inoculated in 25-cm2 culture flasks with 5 ml ofgrowth medium. After 24 hr, various amounts of heparin in phosphate-buffered saline were added to each flask followed by the addition of 1 AM MTX or MTX-poly(Lys) (Mr 3000). After 2 days, the monolayers were re-fed with fresh drug-containing medium. The cell number in each flask was counted on the 5th day and was-compared with that ofuntreated cells.
MATERIALS AND METHODS
Assay ofDihydrofolate'Reductase. The effect ofMTX, MTXpoly(Lys), and MTX-poly(Lys)-polyanion complexes on dihydrofolate reductase was measured by the method of Stanley et aL (8) . When the complexes were used as enzyme inhibitors, MTX-poly(Lys) and the polyanion [heparin or poly(L-Glu)] were incubated together in assay buffer for 1 hr before the addition of substrates and dihydrofolate reductase. However, the reactivation of the inhibitory effect of MTX-poly(Lys) (Mr 3000) by heparin was also observed in freshly prepared mixtures. were detected by a liquid scintillation counter as described (3) .
RESULTS
The biphasic effect ofheparin on the cytotoxicity of 1 ,M MTXpoly(Lys) in two CHO cell lines is shown in Fig. 1 . The cytotoxicity of the conjugate is almost completely abolished by the addition of heparin at 3-10 ,ug/ml; at 30 ,g/ml, however, inhibition of cell growth is partially restored. The drug-resistant MTX-transport-defective cell line (Pro-3 MtxRII5.3) is more susceptible to this restoration than the wild-type line (WT-T); in the presence of heparin at 100 ,ug/ml, -90% growth inhibition can be achieved and drug resistance is almost completely overcome. This restoration of cytocidal action is not due to a toxic effect of heparin itself or to a synergistic effect of heparin and MTX; heparin does not change the effect of free MTX on cell growth and the mutant cells retain their resistance to MTX in the presence of heparin at 100 ,ug/ml (data not shown). The protection against cytotoxicity at low concentrations of heparin is related to a decreased cellular uptake of the polyeationic conjugate due to its interaction with polyanionic heparin (6) .
The addition of heparin at 0.5, 1.0, and 5.0 ,ug/ml to a me- dium containing MTX-poly(Lys) at 2 tig/ml gives a dose-dependent decrease ofuptake that levels offat =17% ofthe control value (Fig. 2) . More heparin fails to depress uptake any further; uptake of the conjugate remains constant at 20-to 50-fold excess heparin. In Unlike the uptake of [3H]MTX-poly(Lys), the residual uptake in the presence of excess heparin is markedly inhibited by addition to the medium of unlabeled poly(Lys) (Fig. 3) , while addition of free MTX has no effect; even at the highest concentration (20 pug/ml) of labeled poly(Lys) used, heparin (100 /Lg/ ml) is still in large excess. This figure therefore illustrates the competition between labeled MTX-poly(Lys)-heparin and unlabeled poly(Lys)-heparin complexes for cellular uptake. The addition of unlabeled poly(Lys) (7.5 ug/ml) inhibited the uptake of uncomplexed [3H]MTX-poly(Lys) by only 10%. At >10 ,ug/ml, free poly(Lys) caused cell lysis. We had reported previously that, when poly(Lys) Of Mr 70,000 was added in 10-fold excess to [3H]MTX-poly(Lys) (0.5 ,ug/ml) of the same Mr, uptake was inhibited by only 19% (3). Therefore, it appears that, unlike MTX-poly(Lys), the MTX-poly(Lys) plain the greater susceptibility of the mutant line to the conjugate-heparin complex (Fig. 1) (B) of heparin at 100 ,g/ml. After treatment, harvested cells were dissolved in 2 ml of 1% NaDodSO4/0.05 M phosphate buffer, pH 7.0. Total radioactivities of the cell extracts were 8 and 1.8 x 104 cpm for A and B, respectively. Aliquots of cell extracts (0.5 ml and 1.1 ml for A and B, respectively) were applied to a Sephadex G-25 column previously equilibrated with NaDodSO4/phosphate buffer. Radioactivity was measured in 0.5-ml aliquots of each 2-ml eluent fraction. MTX, position of marker unlabeled MTX detected by its absorbance at 259 nm; Vt, total column volume.
to 100 ,ug/ml, but it decreases from 50 to 40 when the concentration of poly(Glu) is raised from 10 to 100 ug/ml. When tested in the presence of excess heparin, a conjugate of poly(Lys) and horseradish peroxidase also formed heparin complexes, and the membrane transport of such complexes was also inhibited by the addition of free unlabeled poly(Lys). Horseradish peroxidase-poly(Lys) has previously been used to study the cellular localization of ingested poly(Lys) (1). It was used here to study the entry and cellular localization of poly(Lys)-heparin complexes. In electron microscopic studies, the oxidized reaction products of horseradish peroxidase were found in a variety of endocytotic vesicles and vacuoles (results not shown) indicating that heparin complexes of horseradish peroxidase-poly(Lys), like the conjugate itself (1), enters cells, at least in part, by endocytosis.
DISCUSSION
Our data describe an unexpected effect of heparin-i.e., its ability to restore the cytotoxicity of MTX-poly(Lys) (Fig. 1 ) under circumstances in which it decreases both the net cellular uptake of drug (Fig. 2) and the cellular degradation (and activation) of ingested drug conjugate (Fig. 4) . A clue to an explanation is given by the fact that, in the in vitro assay of dihydrofolate reductase activity, heparin restores the enzyme inhibitory effect of MTX-poly(Lys). Such a reactivation is not totally unexpected. We suggested earlier that the lack of dihydrofolate reductase inhibition by MTX-poly(Lys) was due to its positive charges rather than to its larger size. Macromolecular derivatives of MTX, such as MTX-poly(Glu), are effective inhibitors of this enzyme (9) . It is known that heparin and poly(Lys) form a very stable a-helix with a sulfate/lysyl ratio of 1:1 (10 (13) . A more recent observation indicates that complexing of heparin with poly(Lys) increases internalization of heparin by macrophages (14) .
These changes in transport are associated with differences in the intracellular fate (Fig. 4) and in the pharmacologic potency of MTX-poly(Lys). While the amount of MTX transported into cells is reduced by -85% in the presence of heparin, it can still kill 92% of the drug-resistant cells (Fig. 1) (Fig. 2) . Third, heparin may have specific cellular effects that influence the intracellular fate and ultimate pharmacologic effect ofMTX-poly(Lys)-heparin complexes. It has been reported that polyanions inhibit intracellular digestion of foreign macromolecules by preventing phage-lysosome fusion (18) . An effect of this type is consistent with the finding of Fig. 4 , which shows that cells treated with cytocidal concentrations of MTXpoly(Lys)-heparin complex contain less degradation product of the MTX conjugate than cells treated with uncomplexed drug conjugate. This finding raises the question as to how ingested MTX-poly(Lys)-heparin complexes can escape from the interior of endocytotic vesicles or vacuoles to other cellular compartments and reach the physiologic sites ofdihydrofolate reductase activity. It is conceivable that heparin-containing endocytotic vesicles that fail to fuse with lysosomes have the ability to release their contents into the cytoplasm. It is possible also that excess heparin might improve the accessibility of dihydrofolate reductase and influence its intracellular localization. Together with other nucleotide processing enzymes, this reductase has been found to move from cytoplasm to nucleus at certain phases of the cell cycle (19) . Further studies will be required to determine how poly(Lys) and its heparin complexes differ in their intracellular distribution.
So far, we have detected a specific binding site for poly(Lys)-heparin complexes in two CHO lines, in L929 cells, and in BALB/c 3T3 cells. Depending on its distribution and tissue specificity, this receptor system could be used, as in this case, for overcoming drug resistance due to transport defects of tumor cells or, more generally, for selective drug delivery through drug-carriers that would have the advantages of facilitating access of the drug to its cellular targets and eliminating the undesirable toxicity ordinarily associated with a strong polycationic charge. Heparin can form complexes with several proteins (11, 20, 21) and the possibility should be considered that physiologic or pharmacologic effects of heparin other than its anticoagulant action (11, 20, 22, 23) might be related to the receptor-mediated transport of heparin-polypeptide complexes into target cells.
